drugset / Trial / NCT01718873

Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer

NCT01718873

Phase 3 Completed 230 enrolled National Cancer Institute, Naples
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate if giving bevacizumab prior to chemotherapy compared to giving bevacizumab at the same time as chemotherapy improves patient overall response to treatment.

Timeline

Start
2012-05
Primary completion
2015-12
Completion
2019-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 7.5 mg/kg
Background Capecitabine Small molecule 1000 mg/m2
Background Levoleucovorin Unknown 200 mg/m2
Background Oxaliplatin Small molecule 85 mg/m2
Background fluorouracil Small molecule 2400 mg/m2

Indications